

Project Livin' Label video on sotorasib

Media: Enduring Material

Accredited Activity Release Date: December 1, 2022

Accredited Activity Expiration Date: December 1, 2025

Time to Complete Activity: 90 minutes

Activity Description

The FDA Oncology Center of Excellence (OCE) and AACR are collaborating to launch a new educational initiative Project Livin' Label. The objective of these efforts is to educate the oncology community about select recent oncology drug approvals. The FDA will develop an educational video on a select recent oncology drug approval, discussing aspects found within the drug product label, such as safety findings and efficacy results. The FDA may choose to invite external guests to participate in the discussions. The FDA will share this video with AACR, along with the publicly available drug product label, and AACR will disseminate this information to the oncology community. Oncology practitioners can watch the video and review the associated drug product label and receive credit for this activity. All FDA oncology drug approvals have an approved package insert (US Prescribing Information). There is mixed use of the USPI depending on practice locations and type of practice. In addition, many practitioners are not familiar with the content of the USPI.

Target Audience

This educational initiative intends to educate the oncology practitioners on FDA's thinking behind an oncology drug approval, including discussions on the efficacy and safety findings from the registration trials. The discussions will center around the approval and reference relevant sections in the USPI where this information is located.

Educational Objectives

Upon completion of this activity, participants will be able to:

- Articulate the reasoning behind an FDA oncology drug approval.
- Identify the relevant sections of the drug USPI where information is located.
- Integrate this information into their clinical practice.

Accreditation Statement

AACR designates this enduring material for a maximum of 1.50 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. A statement of credit will be issued only upon completion of the post-activity evaluation form and [post-test](#).

Claiming CME Credit

Physicians and other health care professionals seeking *AMA PRA Category 1 Credit(s)*[™] for this enduring activity continuing medical education activity must complete the online CME Request for Credit Survey. Certificates will only be issued to those who complete the survey. The Request for Credit Survey is available [here](#). Your CME certificate will be sent to you via email after the completion of the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 Maintenance of Certification (MOC) points in the American Board of Internal Medicine's (ABIM) MOC program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared with ABIM through the ACCME's Program and Activity Reporting System (PARS).

Disclosure Statement

It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. All of the relevant financial relationships listed for these individuals have been mitigated.

Faculty Disclosures

Participant Name	Role	Financial Relationships	Type
Nicole Drezner	Program Committee, Moderator	No Relationships	

Richard Pazdur	Program Committee	No Relationships	
Erica Nakajima	Speaker	No Relationships	
Stacy Shord	Speaker	No Relationships	
Grace Dy	Speaker	AstraZeneca, Takeda, GSK, Mirati	A, IC, H
Greg Friberg	Speaker	Amgen	E
John A. Szczesny	Speaker	No Relationships	
Askia Dozier	Speaker	No Relationships	

Relationships are abbreviated as follows: E, Employment; FO, Fiduciary Officer; IC, Independent Contractor; S, Stock; SO, Stock Option; OS, Other Securities; OBO, Other Business Ownership; GC, Grant/Contract; T, Travel; GI, Gift; P, Patent; TM, Trademark, C, Copyright; OIP, Other Intellectual Property; O, Other.

Planning Committee Disclosures

FDA staff involved in the development and review of this activity have disclosed no relevant financial relationships.

AACR staff involved in the development and review of this activity have disclosed no relevant financial relationships.

Questions on CME or CPE

For CME: Please contact the Office of CME at (215) 440-9300 or cme@aacr.org.
For CPE: Please contact HOPA at 877-467-2791 or education@hoparx.org.